Description
欢迎收听最新一期的医学突破播客！今天，我们将聚焦2024年小细胞肺癌（SCLC）治疗领域的重大进展。这项研究为我们带来了希望，特别是在免疫疗法领域，通过durvalumab、tarlatamab和lurbinectedin等新疗法，患者的生存期得到了显著延长，有望实现长期生存。此外，精准医学的应用和生物标志物选择的可行性也在推动SCLC治疗的个性化。最后，新成立的倡导团体Small Cell SMASHERS为患者提供了更多支持。这标志着SCLC治疗革命的到来，开启了对抗这一致命疾病的新时代。不要错过，让我们一起探索这些激动人心的发现！
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Before the Crisis: How You and Your Relatives Can Prepare for Financial Caregiving
06 Dec 2025
Motley Fool Money
Anthropic Finds AI Answers with Interviewer
05 Dec 2025
The Daily AI Show
#2423 - John Cena
05 Dec 2025
The Joe Rogan Experience
Warehouse to wellness: Bob Mauch on modern pharmaceutical distribution
05 Dec 2025
McKinsey on Healthcare
The method of invention, AI's new clock speed and why capital markets are confused
05 Dec 2025
Azeem Azhar's Exponential View
Meta Stock Surges on Plans for Metaverse Cuts
05 Dec 2025
Bloomberg Tech